Here are couple of important press releases.
VIENNA, Va., Feb. 21 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM - News) announces positive results from a long-term follow-up study of head & neck cancer patients treated with its drug Multikine® in a Phase II clinical trial.
VIENNA, Va., Dec. 6 /PRNewswire-FirstCall/ -- On December 5, 2005, CEL-SCI CORPORATION (Amex: CVM - News) announced that it had signed a Cooperative Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health of the U.S. government, to test CEL-SCI's patented anti-infective drug CEL-1000 against the avian (bird) flu virus H5N1 in animal models. The testing will be conducted to determine whether CEL-1000 could be used as a potential treatment and/or preventive agent against this virus.
Fundamentals by Market Guide
* Outstanding Shares : 74.2 mil
* Float : 6.7 mil
* Market Value : $56.41
* Debt : $0.00
* Cash on hand : $1.89 mil
Chart
(http://www.3stocksonfire.org/trading/index.php?action=dlattach;attach=15934;image)
* PROC is Bullish
* CVAD is Bullish
* OBV is Bullish
* RSI is Bullish
* MACD is Bullish
* MA(10) is Bullish
* MA(50) is Bullish
* MACD (weekly) is Bullish
* Stochastic(5) is Bullish
* Price Break (3) is Bullish
Looking Ahead
So, why is CVM getting hot?
IMO, There's something boiling behind the doors. >:D
In next few days, IMO, they will announce FDA approval of go ahead of trial III for Multikine.
or(and), positive result from anti-infective drug CEL-1000 against the avian (bird) flu virus H5N1.
The volume has not picked up yet, but once it does, this stock can gain big time in one day.
That could happend in couple of weeks. IMO
Volume is picking up! ( 830,000) +9.21%, +0.07
This stock never made daily volume of 2 mil. But, looks like it will break that mark this week.
Since all CVM message boards are very quite, I assume that there aren't any day traders involved. So, it is being accumulated.(IMO)
Once the day traders jumps into this stock (or +2mil volume) with or without PR, this will gain 30 to 40% in a day.
Until then I am holding my 40k shares. ;D
As a speculator, I need to speculate to make money.
We had this news on CVM and the stock has been rising ever since:
Multikine Treatment Increases Survival in Cancer Patients (http://biz.yahoo.com/prnews/060221/cltu506.html?.v=25)
I think there's plenty of room for speculation here, since this company has just $62.35M in market cap.
Some more highlights:
- «The follow-up study indicated that Multikine treatment resulted in a substantial increase in the survival of patients. In addition, Multikine treatment also improved local regional control of the patients' tumors. Improved local regional control of the tumor is considered by many surgeons and oncologists to be an important measurement of the success of a head & neck cancer drug. Both survival and local regional control of the tumor are stated endpoints in CEL-SCI's planned Phase III clinical trial.»
- «Maximilian de Clara, President of CEL-SCI, states, "These results suggest that Multikine has the potential to bring much needed benefit to patients with head & neck cancer, a disease that has significant morbidity and mortality and for which there has been little improvement in therapy over the last 20 years. We are very excited by these results and hope to repeat these very promising results in our Phase III clinical trial."»
- «CEL-SCI received the go-ahead for its proposed Phase III trial from the Canadian drug regulatory authority in August 2005. The same proposed Phase III trial was submitted to and discussed with the United States Food and Drug Administration (FDA) in two separate End of Phase II meetings held during 2005. Following each of these meetings the FDA requested that additional information be provided. CEL-SCI has recently completed the submission of all of the additional information the FDA requested and awaits the FDA's response.»
- «Head and neck cancer is an aggressive cancer that affects about 500,000 people per annum worldwide. About 92% of those cases are outside of the U.S., and about two thirds of all cases present with advanced disease.»
CVM was an out of favor biotechnology company. Possibly this news has the potential to put it back in favor again, to a $150 to $200M market cap, over the short term (say, 2 or 3 months).
Unfortunately I don't know enough to judge if these findings are truly important or not. But I know the stock is rising and volume is also rising, so the trend is bullish. The trend is my friend and I'll go with it, buying CVM around today's open for the Stocks on Fire Portfolio, 6.66% of capital as usual.
What do you know? CVM was up so much and bingo, up again yesterday !
Volume also increased to 1.8 million shares.
Even on a short term basis I should let the profits run, perhaps I have a big winner here, and the recent rise will be a minuscule thing down on the chart.
Price and volume rising tells me I should continue holding, because higher prices will come.
gap up?!? :o
There is an exclusive interview with the CEO on this website: wallst.net
Good Pick David ! ;D
Quote from: danman3459 on March 01, 2006, 08:17:35 AM
gap up?!? :o
When you wrote «gap-up» I thought I should change my analysis and recommend selling the stock, because usually a steep run up like this ends with a gap up.
But I thought: «I don't know what the man said on the interview, this thing can go sharply higher since the market cap is so low, I'll better stay the course».
Then I went out for lunch and went to Stocks on Fire LLC office (actually now I work mostly at home), and saw the stock up 15%. I made a scroll up on this thread and looked at the descending trendline on the medium term chart:
«Damn it, we hit resistance, this thing won't hold».
But, I couldn't do anything, since 3 Stocks on Fire is an end of the day trading service. I forgot to consider that resistance line and give specific instructions to sell at it, so I held.
The stock collapsed from the highs to close at $0.89. The correction was probably due, because the stock was extremely overbought.
So I consider this «normal market behaviour», or «profit taking», as you like. Market cap is still just $66M, but it went to $79M intraday. I would say that if this company went over $100M it would be «fully valued», or «overvalued», with the information I have now.
I tell you this: if I can sell at $1 today, I'll do it. Otherwise, I'll continue holding.
Sell order at $1.00 should be given yesterday!!
Another trade which turned a gain to a loss.
This should never happen.
If you have a gain of at least 5%, should not let the gain slepped away.
Shawfund, you think CVM is done going up ??
With stocks gained 100% in few days, most will dump the stock to take profit.
Risks will be much higher buying after it gained 100% in short term.
But may be, it will bounce back after retracement.
What I am saying is that we should not let the profit slepped away if it is greater than 5%.
shawFund is right, we all know that. But practice is often harder than theory.
Of course I should have sold it at $1, since now it is at $0.78, but should I sell now is the important question. I don't think I should, as the stock is trading at its 50% retracement level, after a quite normal pullback of an oversold condition.
I think CVM will bounce back and possibly even make new highs above $1.06.
I'll continue holding the stock for now.
Some news came out........
CEL-SCI Corporation Releases Letter to Shareholders
Wednesday March 8, 11:46 am ET
VIENNA, Va., March 08 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI CORPORATION (Amex: CVM - News) to its shareholders:
ADVERTISEMENT
Dear Fellow Shareholders:
CEL-SCI set out to create a cancer therapy that would work with the body, not against it; a cancer therapy that would help patients conquer their cancer with the first cancer treatment so that the cancer will not recur. We are pleased to report that recently analyzed follow-up data from the key Phase II clinical trial with our cancer drug Multikine® indicate that the drug had a substantial effect on the survival of the patients treated with it.
The long-term follow-up study of the head & neck cancer patients who received Multikine over 3 years ago showed a substantial improvement in both the survival rate and the local regional control of their tumors. The detailed results of this follow-up study are currently being prepared for publication in a scientific journal. These data, if confirmed in our planned Phase III clinical trial, would represent a huge step forward in the treatment of head & neck cancer patients.
The benefit of survival to the patient is obvious and survival is the gold standard of cancer drug development. Increased local regional control refers to the increased ability to delay the recurrence of the tumor in the head & neck area. If a drug can delay the recurrence of the tumor, the patient will have much improved life for the period during which there is no recurrence of disease. Clearly this is a meaningful benefit to the every-day life of a cancer patient, and in particular to a head & neck cancer patient, where local control often means preserving the ability to swallow, breathe and talk without assistance.
In our October 2005 letter to the shareholders we highlighted the three major contributions Multikine makes in fighting cancer and postulated that these contributions should lead to an increase in the success rate of the cancer treatment. We now have Phase II data that shows improved local regional control of the tumor as well as increased survival and we are therefore able to support our original hypothesis. Our next goal is to repeat these results in the planned Phase III clinical trial where the endpoints are the same as those that we measured in the follow-up study: local regional control of the tumor and survival.
The planned Phase III study already has been cleared for go-ahead by the Canadian regulators and CEL-SCI is currently awaiting word from the U.S. FDA. Since most of the head & neck cancer patients are outside of the U.S., we hope to conduct one worldwide Phase III study, including the countries of our Asian partner Orient EuroPharma, for drug approval.
We proceed on one simple assumption. If we can show clinical benefit by demonstrating increased survival or improved local regional control, or better yet, both, Multikine should end up being used as first-line therapy in head & neck cancer, 5% of all cancers worldwide. Ultimately it may even be useful in treating many other cancers as well. And, it cannot be stated often enough, Multikine has been essentially non-toxic. If we can achieve this, meeting worldwide demand for Multikine would likely become our challenge.
Let us again state the obvious: "If the cancer does not recur, you will have a much greater chance of survival." That is our goal and the reason for adding Multikine to the standard first-line cancer therapy.
On a different note, we reported late last year that CEL-SCI had signed an agreement with the National Institute for Allergy and Infectious Diseases (NIAID), whereby NIAID agreed to test our CEL-1000 drug against the avian flu virus in animal models, which are very hard to come by. CEL-1000 is very interesting because it has protected against different viruses and parasites in animal models. Such broad based protection by CEL-1000 would be very helpful against the avian flu virus, as it undergoes constant mutation.
After discussions with avian flu virus experts we have decided that more research in the area of the avian flu virus infection and treatment with CEL- SCI products can and should be done. In conjunction with these experts we have developed a plan to test CEL-SCI products against the avian flu virus. The testing performed under this plan will be in addition to the testing of CEL-1000 that is currently being done by the NIAID. Some of what we are doing and plan to be doing will be obvious, but a lot of it focuses on areas that have not yet been highlighted in the popular press as areas in need of help. We will update you in the future on this program as it progresses.
We thank you for your support.
Sincerely,
Geert Kersten Maximilian de Clara
Chief Executive Officer President
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2004. The Company undertakes no obligation to publicly release the result of any revision to these forward- looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Hi Realdeal,
I read this one time, two times and three times and then I bought the stock. (I am a bit slow ;))
This is a phase II study and we are still years away from Commercial launch. Here is the bad news. I don't think this company will survive till Commercial Launch (http://www.3stocksonfire.org/trading/index.php?action=dlattach;attach=4982)
I think they will have been bought up long time before that.
Most major Pharma are desperate to add new drugs to their pipeline. They are facing increasing generic competition and they don't have drugs to replace the drugs that are facing competition. They have been sleeping while small biotechs have developed Cancer medicine and other drugs to highly profitable lethal diseases. They have instead been researching sleeping pills and headache tablets.
We all know Merck, their Market Cap is 76.3 billion. Eli Lilly's Market Cap is 63.9 billion. How many outside the medical and investing community knows about Amgen (market cap 91.1 Billion or Genentech market cap (87 Billion). The truth is that not many years ago Merck and Eli Lilly could easily have bought these companies.
CelSci's market cap is 61 million. Could it be multi billion dollar company. I don't know and I don't think we will ever know. I think they are going to be bought long before that.
I am most likely wrong but that doesn't matter too much because I am very comfortable holding the stock until we find out.
Mike
I'm glad I wasn't around when the stock dropped to $0.70 ... or I would feel even worse.
What matters now is it closed on a strong note, with volume above average. I'm glad Michael bought the stock. He knows a lot about drug companies :)
I also read the news and I wish the company succeeds in its pursuit for a cancer treatment. If not the company, its product, owned by another company, as Michael says.
I know that to say this is boring, but stocks do not go up in a straight line. They often pullback (almost always) and then the trend continues. The trend on CVM is bullish and the market cap is quite low, if we consider the pursuit the company is involved. There's plenty of space for speculation, as the title of this thread implies.
It's getting harder and harder to buy and hold stocks for a period of time. Day trading and very short term position trading reigns supreme right now. I can be a day trader or a fast position trader, but only playing the game alone.
I know I should have sold above $1 and buy back below $0.80. But I didn't.
That's the past and nobody can change the past, so why should I think about it?
What matters is the current situation, and at this point I will continue holding CVM.
Not a particularly good day for CVM, but nothing has affected the short term pattern yet, which is still bullish. The stock had its first run, hit the resistance level and now it's trading a bit bellow (20%) with low volume...
I really enjoyed David's call on CVM, and Michael's opinion too... We may still have some potential here, even if things are not so nice on the short term (low volume / lack of upside reaction), the same I can't say on the long term patterns (long term semi-log chart attached).
There are 2 downside levels that could be supports: 0.75 and 0.70, even if I don't like having so much room, I enjoy the risk / reward ratio on this one, so we'll use $0.69 stop level and let this pattern rolling on.
Best regards !
CVM is loosing momentum, volume is low, and we had another red day on this stock. The $0.75 support was tested again, creating a small reaction there, but nothing serious.
It possible that the «green light» takes a bit more days to come, although we'll still be using the $0.69 stop level on this trade and wait developments.
Best regards,
Ramsburg.. This is a goodsupport area..67.-70. I see why you used .69 but I am selling on a close below .67.. not just a print.. An announcement is inniment in my opinion from company on there most promising product.. Could go either way..
Madge
Quote from: madge20 on March 24, 2006, 01:13:44 PM
Ramsburg.. This is a goodsupport area..67.-70. I see why you used .69 but I am selling on a close below .67.. not just a print.. An announcement is inniment in my opinion from company on there most promising product.. Could go either way..
Madge
Your plan is also solid... Since $0.69 is also a strong technical reference, it may act as a good support, and your $0.67 level is a good spot... (I let you my updated chart in attach)
By some reason our stop at $0.69 didnt sell our position, but in order to follow the plan we sold immediately at $0.70.
PS: CVM will remain on our watch list.
CEL-SCI Files Patent for Prevention/Treatment of Bird (Avian) Flu
Tuesday , April 04, 2006 09:45 ET
VIENNA, Va., April 4, 2006 /PRNewswire-FirstCall via COMTEX/ -- CEL-SCI CORPORATION (Amex: CVM) announces that it has filed a provisional U.S. patent application covering its drug CEL-1000 for the prevention/treatment of bird flu and/or as an adjuvant to be included in a bird flu vaccine.
Geert Kersten, Chief Executive Officer of CEL-SCI said, "By filing this patent in the U.S., we are preserving our rights to file patents on this invention world-wide."
CEL-1000, when used as a single adjuvant (enhancer of a vaccine) or in combination with other adjuvants, potentiates Th1 (cellular) and innate (earliest stage) immune responses and protects animals from viral and parasitic challenge. CEL-1000 provides antigen-independent (i.e., non-disease specific) and broad-spectrum protection upon challenge with the disease causing agent(s), which is important against the bird flu virus since it exhibits a high mutation rate.
CEL-1000, is a patented defined amino acid sequence derived from the beta chain of human MHC-II, which itself is a modified version of a human immune- based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective immune response. It is a defined peptide, which binds to the CD4 and/or likely a related molecule LAG-3 on dendritic cells, macrophages and T cells, thereby promoting the release of cytokines responsible for activating a protective Th1 immune response (e.g., IL-12 and upon challenge IFN-gamma).
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.
When used in this report, the words "intends," "plans," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Ramsburg.. wanted you to know I held and Kudos to your screening and pick! I would have never owned had you not pointed out this company to me...
Sold today at an average of 1.60.. still monitoring for future.. let's see what happens tommorrow.
Madge
Quote from: madge20 on April 04, 2006, 05:31:44 PM
Ramsburg.. wanted you to know I held and Kudos to your screening and pick! I would have never owned had you not pointed out this company to me...
Sold today at an average of 1.60.. still monitoring for future.. let's see what happens tommorrow.
Madge
Madge and others,
I own a bunch of shares from 1.44 - What do you suggest I do with this one??? Let it run or sell tomorrow morning for a nice 20% gain...?
Thanks,
calven >:D
RAMS - Would love your thoughts on tomorrow's price action here...
Normally I would take profits with the recent 110% run but with so much volume behind it, I think it may want more....
Wow this would have been a nice one to have held onto. I didn't play it but I've been in similar situations as the 3Stocks crew is here -- cutting for a loss and then a week later it blasts off. Probably most of us have.
Madge, congrats on the gain! But what happened to "I am selling on a close below .67" ;) It closed at .66 one day last week. You've made a good case against those who advise "never break your trading rules." Rules? We don't need no stinkin' rules! It's all about the Hamiltons baby ;D
I don't think you should have sold though. I'd have held for a gap up tomorrow, in case it gapped like BDCO did on Monday. You probably had a 100% gain though - hard to resist taking those profits. Very nice $-)
Calven,
Looks like some daily support right now at 1.28. I am looking to reneter at 1.08-1.10 if it gets there... Definitely stop out if it closes below 1.05.. Long term its a toss up .. Don't know if there product will be " it"!
Quote from: madge20 on April 05, 2006, 11:53:14 AM
Calven,
Looks like some daily support right now at 1.28. I am looking to reneter at 1.08-1.10 if it gets there... Definitely stop out if it closes below 1.05.. Long term its a toss up .. Don't know if there product will be " it"!
Im in from 1.44 and now down on the position.... what do you guys make of today's price action? Will it retest highs next week?
cal >:D
I was surprised by the gap down. Madge, I was wrong and you were right. Nice exit! $-)
Yabadabado ;D
At what price did you pikc up CVM ??
CVM seems to have formidable resistance at 1.50... Testing highs of the session. We'll see how this one shakes out.
1.690 - 1.70 gap fill
Avg. $0.70
will hold all my shares, since it looks like it has more room to move.
http://abcnews.go.com/GMA/AvianFlu/story?id=1716820&page=1
bird flu on its way to amerika
18 dead swans (?) Vienna CNBC eom
I bought some today... I feel this one will break soon on the upside.. I think 1 or 2 more candlestick will fit in that little Symmetrical Triangle... & BOOM... ;)
I'll put a tight stop on this I maybe wrong ;)
BULL POWER is strong, let's see...
Calven, r u still in with this one?
I dont think this one is going to break upwards but I could be wrong...reason being:
Stock shot up to 1.78
Retraced to 1.20 and gradually rose higher - on lower volume
This lower volume recovery candles seem weak to me...actually seems like bulls are losing their breath..I obviously could be wrong.
Still in (half position) but praying for news over the weekend or early next week. I dont think technicals are helping us here...
-cal >:D
Picked some up on Friday, also with a tight stop. We'll see what happens ::)
Well...of course it dropped as soon as I bought it ::). Pleased to see it making a bounce today on decent volume, thus far..
CVM lookin nice today bouncing off long term support at 1.10, bouncing off the 61.8% fib retracement, and forming a text book morning doji star pattern. Im in at 1.26, Last AH quote i saw was up another 7.5%.
Anyone else still holding this rocket?
-fous
Morning Doji Star
Significance: bullish
Indication: reversal
# of candles: 3
Previous Trend: Bearish
The Morning Doji Star pattern is characterizes by 3 candles. The fisrt day is a long black candle reinforcing the already bearish downtrend. The second is gaps down and forms a doji candle, indicating confusion in the market and a reversal could be upon us. And finally the 3rd day forms a white candle whose closing price pushes well into the real body of the first black day that occurred in this pattern. A gap up on the 3rd day is preferred for an ideal bullish Morning Star pattern though is not required. Confirmation of this pattern is provided by a higher close on the 4th day.
Note: Candlestick reversal patterns are significantly more potent when occuring near areas of support and resistence.
You got it right fousc... i still think this one will come up.. weekly MACD-Histogram still tracing up, i'll take that a sign that the pullback is done ;)
Hi Everyone,
This is my very first post and really enjoying this board. Anyhow, I think I'm going in this on Monday as well. Correct me if I am wrong but is this chart resembling a flag formation? Is that one of the most bullish charts?
Thanks!
fous-
Yeah, I'm still in. I was tempted to sell to cut losses, as I'd picked this up at around 1.50. Glad I didn't; really looking forward to seeing this pattern play out on monday. GLTA!
bird its getting hot
http://www.washingtonpost.com/wp-dyn/content/article/2006/04/15/AR2006041500901_pf.html
Long: 1.26
Last: 1.28
Stop: 1.20
Target: $$
-fous
AP
Cel-Sci Shares Soar on Study News
Tuesday May 23, 5:40 pm ET
Cel-Sci Says Drug Candidate Improves Long-Term Survival of Cancer Patients in Study
VIENNA, Va. (AP) -- Shares of biotechnology company Cel-Sci Corp. surged Tuesday on news of a successful mid-stage clinical trial of its cancer drug candidate Multikine.
In the Phase II study, the company measured long-term survival rates of patients who have undergone surgery for a head and neck cancer called oral squamous cell carcinoma.
Nearly 40 published studies between 1987 and 2004 show that the median survival rate 42 months after surgery for the disease is about 47 percent using standard of care treatment. CEL-SCI found the survival rate from standard of care treatment plus Multikine to be 67 percent.
The next step, a Phase III clinical trial, has already been approved. It would bring in a substantially larger pool of participants to further test the effectiveness of the treatment.
Head and neck cancer affects 500,000 people worldwide each year.
Cel-Sci stock gained 22 cents to close at $1.07 on the American Stock Exchange before adding 3 cents in after-hours trading. Shares have ranged between 44 cents and $1.78 over the past year.
OK, back above the 50-day MA.
moved nicely today, with some volume.
Volume: 2,110,500
Avg Vol (3m): 1,215,070
Up in the after hours and rising,
CEL SCI CP (AMEX:CVM) Delayed quote data
After Hours (RT-ECN): $1.16 0.09 (+8.41%)
Technicals
Most Actives
Percentage Gainer
Last Price Quote is:
11.23%above 13-day EMA
6.91%above 50-day EMA
RS Rating: 98
Fundamentals
Key Data:
Market Cap (M): $49.87
Everybody's gone away, seems they left 3SOF for another place... :( :'(
No updates since May 2006 :o
Is there anyone left out there...10435 Members ???
Something is up.
Look at the volume...there is something significant about the huge volume that we saw yesterday accompanied by the big price spike! Volume don't Lie...
Something big, could very well be around the corner.
CEL-SCI Corp collaborators demonstrate novel L.E.A.P.S. vaccines immunize mice against Tuberculosis antigens and "suggest potential to treat swine and other influenzas" Co announces that its collaborators at the University of Hawaii reported on data at the annual American Society for Microbiology in Philadelphia, PA. This data demonstrates that vaccines utilizing its L.E.A.P.S vaccine technology with specificity for particular Mycobacterium tuberculosis antigens can elicit immune responses that would be protective against tuberculosis and have the potential to treat swine and other H1N1 influenzas.
Strong Uptrend
CEL-SCIENCE CORP (AMEX:CVM)
Smart Scan Chart Analysis confirms a triangle indicates the presence of a very strong trend that is being driven by strong forces and insiders.
52wk Range: 0.14 - 0.80
Volume: 32,369,642
Avg Vol (3m): 1,211,560
Technicals
Record Volume
Record Price High
Most Actives
Record Price Break Out
Percentage Gainer
Last Price Quote is:
82.74%above 13-day MA
110.84%above 50-day MA
RS Rating: 95
Fundamentals
Key Data:
Market Cap (M): $49.87
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: N/A
Everybody's gone away, seems they left 3SOF for another place... :( :'(
No updates since May 2006 :o
Is there anyone left out there...10435 Members ???
Something is up.
Look at the volume...there is something significant about the huge volume that we saw yesterday accompanied by the big price spike! Volume don't Lie...
Something big, could very well be around the corner.
CEL-SCI Corp collaborators demonstrate novel L.E.A.P.S. vaccines immunize mice against Tuberculosis antigens and "suggest potential to treat swine and other influenzas" Co announces that its collaborators at the University of Hawaii reported on data at the annual American Society for Microbiology in Philadelphia, PA. This data demonstrates that vaccines utilizing its L.E.A.P.S vaccine technology with specificity for particular Mycobacterium tuberculosis antigens can elicit immune responses that would be protective against tuberculosis and have the potential to treat swine and other H1N1 influenzas.
Strong Uptrend
CEL-SCIENCE CORP (AMEX:CVM)
Smart Scan Chart Analysis confirms a triangle indicates the presence of a very strong trend that is being driven by strong forces and insiders.
52wk Range: 0.14 - 0.80
Volume: 32,369,642
Avg Vol (3m): 1,211,560
Technicals
Record Volume
Record Price High
Most Actives
Record Price Break Out
Percentage Gainer
Last Price Quote is:
82.74%above 13-day MA
110.84%above 50-day MA
RS Rating: 95
Fundamentals
Key Data:
Market Cap (M): $49.87
P/E Ratio: NA
PEG Ratio: N/A
Next Earnings: N/A
Last Analyst Rating: N/A
I guess I had some stocks flagged to notify me of any change. And tonight I was surprised when I saw and old familiar name. It amazed me that someone I had respected so much was commenting on a stock that just tonight I had flagged to watch closely.
Yes, I'm afraid I took off after awhile. I enjoyed the early days around here so very much. But alas I could not be a paid subscriber and did not wish to take advantage of David and his hard work. Just did not seem ethical to me at that time. But I still miss the cumlautery we once had around the old 3SoF homestead.
Thanks for the post
I'll surely watch CVM more closely now.
Art
Thanks for the visit, hope to see you more often!
Watch on this one...
could be forming a Double Bottom (reversal) chart pattern here.
Day's Range: 0.50 - 0.5450
52wk Range: 0.43 - 1.05
Volume: 1,343,073
Avg Vol (3m): 724,742
Technicals
Last Price Quote is:
-6.62%below 13-day EMA
-14.94%below 50-day EMA
RS Rating: 29